Načítá se...
Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection
BACKGROUND: The safety of immune checkpoint inhibitors (ICIs) in patients with hepatitis C virus (HCV) infection has not been studied in many cancers, as these patients were excluded from most ICI trials. This poses a degree of uncertainty when a patient with HCV is being considered for ICIs in the...
Uloženo v:
| Vydáno v: | Oncologist |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Inc.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8100564/ https://ncbi.nlm.nih.gov/pubmed/33655663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13739 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|